Sign in or create an account to add this stock to your watchlist.
About Krystal Biotech (NASDAQ:KRYS)
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KRYS
CUSIPN/A
Phone412-586-5830
Debt
Debt-to-Equity RatioN/A
Current Ratio105.91
Quick Ratio105.91
Price-To-Earnings
Trailing P/E Ratio-6.88
Forward P/E Ratio-4.61
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.60 per share
Price / Book2.21
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees12
Outstanding Shares10,310,000
Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions
What is Krystal Biotech's stock symbol?
Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How were Krystal Biotech's earnings last quarter?
Krystal Biotech (NASDAQ:KRYS) released its earnings results on Monday, May, 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.27. View Krystal Biotech's Earnings History.
What price target have analysts set for KRYS?
1 equities research analysts have issued 1 year price objectives for Krystal Biotech's stock. Their predictions range from $23.00 to $23.00. On average, they expect Krystal Biotech's stock price to reach $23.00 in the next year. View Analyst Ratings for Krystal Biotech.
Who are some of Krystal Biotech's key competitors?
Some companies that are related to Krystal Biotech include PDL Biopharma (PDLI), Idera Pharmaceuticals (IDRA), Nightstar Therapeutics (NITE), Adverum Biotechnologies (ADVM), Agenus (AGEN), Jounce Therapeutics (JNCE), NanoString Technologies (NSTG), Cellular Biomedicine Group (CBMG), Allena Pharmaceuticals (ALNA), NantKwest (NK), Osiris Therapeutics (OSIR), Arsanis (ASNS), ADMA Biologics (ADMA), Organovo (ONVO) and Fennec Pharmaceuticals (FENC).
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the folowing people:
- Mr. Krish S. Krishnan M.S., M.B.A., Pres, CEO & Chairman (Age 53)
- Ms. Suma M. Krishnan, Founder, COO & Director (Age 53)
- Ms. Pooja Agarwal, VP of Product Devel.
- Mr. Michael C. Sheahan CPA, Interim Chief Financial Officer
When did Krystal Biotech IPO?
(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.
Has Krystal Biotech been receiving favorable news coverage?
News headlines about KRYS stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Krystal Biotech earned a daily sentiment score of 0.09 on Accern's scale. They also gave news coverage about the company an impact score of 46.62 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Krystal Biotech's major shareholders?
Krystal Biotech's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.17%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.
Which institutional investors are selling Krystal Biotech stock?
How do I buy shares of Krystal Biotech?
Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Krystal Biotech's stock price today?
One share of KRYS stock can currently be purchased for approximately $10.18.
How big of a company is Krystal Biotech?
Krystal Biotech has a market capitalization of $108.25 million. The company earns $-7,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Krystal Biotech employs 12 workers across the globe.
How can I contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.
MarketBeat Community Rating for Krystal Biotech (KRYS)
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Krystal Biotech (NASDAQ:KRYS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Krystal Biotech in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible upside of 125.93%. The high price target for KRYS is $23.00 and the low price target for KRYS is $23.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.00 | $23.00 | $23.00 | $23.00 |
| Price Target Upside: | 125.93% upside | 136.87% upside | 136.87% upside | 136.87% upside |
Krystal Biotech (NASDAQ:KRYS) Consensus Price Target History
Krystal Biotech (NASDAQ:KRYS) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/18/2017 | Ladenburg Thalmann | Initiated Coverage | Buy ➝ Buy | $23.00 | N/A |  |
(Data available from 5/25/2016 forward)
Krystal Biotech (NASDAQ:KRYS) Earnings History and Estimates Chart
Krystal Biotech (NASDAQ:KRYS) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.21 EPS
Next Year EPS Consensus Estimate: $-2.41 EPS
Krystal Biotech (NASDAQ KRYS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/7/2018 | 3/31/2018 | ($0.48) | ($0.21) | | | View | N/A | |
| 11/13/2017 | Q3 2017 | ($0.74) | ($1.26) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Krystal Biotech (NASDAQ:KRYS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Krystal Biotech (NASDAQ KRYS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 45.80%
Institutional Ownership Percentage: 29.82%
Krystal Biotech (NASDAQ KRYS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/22/2018 | Antony A Riley | CFO | Buy | 2,800 | $10.75 | $30,100.00 | | |
| 5/9/2018 | R Douglas Norby | Director | Buy | 9,000 | $10.42 | $93,780.00 | | |
| 3/19/2018 | Krish S Krishnan | Insider | Buy | 50,000 | $11.00 | $550,000.00 | | |
| 9/22/2017 | Daniel Janney | Director | Buy | 200,000 | $10.00 | $2,000,000.00 | | |
| 9/22/2017 | Suma Krishnan | COO | Buy | 100,000 | $10.00 | $1,000,000.00 | 1,935,249 | |
(Data available from 1/1/2013 forward)
Krystal Biotech (NASDAQ KRYS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Krystal Biotech (KRYS) CFO Antony A. Riley Purchases 2,800 Shares
www.americanbankingnews.com - May 24 at 8:17 PM |
 | Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
seekingalpha.com - May 24 at 4:22 PM |
 | BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103
www.reuters.com - May 24 at 9:46 AM |
 | U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa
finance.yahoo.com - May 24 at 9:46 AM |
| Krystal Biotech (KRYS) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:41 PM |
| Krystal Biotech (KRYS) Director Buys $93,780.00 in Stock
www.americanbankingnews.com - May 11 at 8:21 PM |
 | Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class
www.nasdaq.com - May 10 at 9:51 AM |
| Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
finance.yahoo.com - May 10 at 9:51 AM |
| Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation
finance.yahoo.com - May 9 at 9:40 AM |
| Krystal Biotech (KRYS) Issues Earnings Results
www.americanbankingnews.com - May 8 at 12:44 PM |
| Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 7 at 9:28 AM |
| ValuEngine Upgrades Krystal Biotech (KRYS) to "Hold"
www.americanbankingnews.com - May 3 at 11:51 PM |
| FDA on board with clinical development of Krystal Biotech's KB103 for skin blistering disorder; shares up 3%
seekingalpha.com - April 26 at 10:16 AM |
| BRIEF-Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa
www.reuters.com - April 26 at 9:26 AM |
| Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
finance.yahoo.com - April 26 at 9:26 AM |
| Krystal Biotech's KB103 an Orphan Drug in Europe for DEB
seekingalpha.com - April 19 at 4:30 PM |
 | Krystal Biotech receives approval in Europe for gene therapy treatment
www.bizjournals.com - April 19 at 4:30 PM |
| Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
finance.yahoo.com - April 19 at 9:41 AM |
| Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio
seekingalpha.com - April 18 at 4:33 PM |
| Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
finance.yahoo.com - April 18 at 4:33 PM |
| Reader Inquiry: Why Is Krystal Biotech Not Participating In The Rally In Gene Therapy Stocks?
seekingalpha.com - April 17 at 9:58 AM |
| Ladenburg Thalmann Financial Services Begins Coverage on Krystal Biotech (KRYS)
www.americanbankingnews.com - April 6 at 3:32 PM |
| Zacks Investment Research Upgrades Krystal Biotech (KRYS) to Hold
www.americanbankingnews.com - March 30 at 11:10 PM |
| Krystal Biotech submits IND for gene therapy KB103 for rare skin blistering disorder
seekingalpha.com - March 27 at 10:07 AM |
| Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
finance.yahoo.com - March 27 at 10:07 AM |
| Krystal Biotech Inc (KRYS) Insider Buys $550,000.00 in Stock
www.americanbankingnews.com - March 19 at 7:28 PM |
| Krystal Biotech (KRYS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 17 at 2:08 PM |
| Krystal Biotech Reports 2017 Financial Results and Business Progress
finance.yahoo.com - March 12 at 10:36 AM |
| Krystal Biotech Inc's Lock-Up Period Will End on March 19th (NASDAQ:KRYS)
www.americanbankingnews.com - March 12 at 1:24 AM |
| Krystal Biotech, Inc. to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 9:57 AM |
| Krystal Biotech, Inc. Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin Diseases
finance.yahoo.com - January 16 at 8:56 AM |
| Zacks Investment Research Downgrades Krystal Biotech (KRYS) to Sell
www.americanbankingnews.com - December 24 at 11:12 AM |
| Krystal Biotech, Inc. (KRYS) Announces Quarterly Earnings Results, Misses Estimates By $0.52 EPS
www.americanbankingnews.com - November 14 at 10:32 AM |
| BRIEF-Krystal Biotech reports qtrly loss per share $1.26
www.reuters.com - November 14 at 1:56 AM |
| Krystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 13 at 8:55 PM |
 | Krystal Biotech (KRYS) Announces KB103 Granted Orphan Drug Designation by FDA to Treat Patients With DEB
www.streetinsider.com - November 9 at 7:46 AM |
| Krystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa
finance.yahoo.com - November 8 at 12:47 PM |
| Krystal Biotech Receives Equity-Based Award from EB Research Partnership and EB Medical Research Foundation
finance.yahoo.com - November 3 at 1:13 PM |
| Krystal Biotech Inc's Quiet Period To Expire on October 30th (NASDAQ:KRYS)
www.americanbankingnews.com - October 23 at 1:22 AM |
| Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock?
finance.yahoo.com - October 21 at 5:31 AM |
| Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of Shares
finance.yahoo.com - September 26 at 8:07 AM |
| Krystal Biotech Inc (KRYS) COO Suma Krishnan Purchases 100,000 Shares
www.americanbankingnews.com - September 25 at 7:14 PM |
| Krystal Biotech Inc (KRYS) Director Daniel Janney Acquires 200,000 Shares
www.americanbankingnews.com - September 25 at 7:14 PM |
| Krystal Biotech Prices IPO at $9.00-$11.00 Per Share (KRYS)
www.americanbankingnews.com - September 8 at 1:24 AM |
Krystal Biotech (NASDAQ:KRYS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Krystal Biotech (NASDAQ:KRYS) Income Statement, Balance Sheet and Cash Flow Statement
Krystal Biotech (NASDAQ KRYS) Stock Chart for Friday, May, 25, 2018
Loading chart…
